NCT05243550 2024-11-04ENVISIONUroGen Pharma Ltd.Phase 3 Active not recruiting240 enrolled 20 charts 1 FDA
NCT03018418 2024-09-19Proton Therapy in Reducing Toxicity in Anal CancerUniversity of CincinnatiPhase 2 Active not recruiting14 enrolled 14 charts